Zimbabwe has declined a major American health deal worth $367m (£272m) spanning five years due to the United States' demand for confidential biological samples.
The decision was revealed after a official document from December was disclosed, which showed President Emmerson Mnangagwa deemed the deal was "unbalanced".
An official spokesman has since explained that the US was demanding access to biological samples for research and commercial gain but was not willing to share the benefits from any future vaccines.
"We must now begin the difficult and regrettable task of scaling back our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had donated more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged more negotiations to reach a deal suitable to both sides so the nation's critical HIV programme can be sustained.
Broader Context
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a high court halted a similar health funding agreement after legal challenges were raised about the safety of citizens' medical information.
Since returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
The agency had overseen assistance for the US government, but Trump claimed its expenditure was "wasteful" and his administration was pursuing direct bilateral deals to enhance transparency and responsibility.
As per reports, 16 African countries have so far agreed to these new agreements, constituting more than $18.3bn of fresh investment.
Details of the Declined Agreement
This assistance for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this collaboration might have yielded immense benefits for Zimbabwean communities, particularly the 1.2 million currently on antiretroviral therapy via American-funded programmes," Tremont added.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to share its biological resources and data over an extended period, without any equivalent guarantee of benefiting from any medical innovations – like new medicines or tests – that might result from that shared data," Mangwana explained.
"Put simply, our nation would provide the raw materials for scientific discovery without any certainty that the resulting innovations would be accessible to our population if a future disease outbreak emerge."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were disrupting frameworks previously established via the global organization.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to manage future global health emergencies.
"This framework is intended to guarantee that when a country provides its data, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the capability to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage continued discussions with our American counterparts on how subsequent collaboration could be structured in a way that honours the sovereignty and interests of both nations."
Medical Community Reaction
Medical experts expressed it acknowledged the government's concerns, but urged that talks must proceed since much of the nation's Aids initiatives were funded by external financing.
"In cases where specific concerns exist, such as those involving information security or implementation frameworks, these can frequently be addressed through technical clarification and negotiated safeguards," it said.
The situation underscores the complex debate between receiving crucial international aid and safeguarding national sovereignty in an ever more data-driven world.